HiFiBiO Therapeutics
Focus: HiFiBiO Therapeutics is a Cambridge-based biotech company founded in 2017 that leverages single-cell technologies for drug discovery, currently focused on oncology therapeutics. The company is in early-stage development with a pipeline of Phase 1programs across multiple cancer indications.
Profile data last refreshed 7h ago · AI intelligence enriched 6d ago
Open Jobs
0
About HiFiBiO Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow HiFiBiO Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from HiFiBiO Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
HFB30132A
HealthyClinical Trials (1)
NCT05275660A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults
Phase 1Help build intelligence for HiFiBiO Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.